Eli Lilly And Company (LLY): Today's Featured Drugs Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Eli Lilly and Company ( LLY) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 0.5%. By the end of trading, Eli Lilly and Company fell $0.61 (-1.1%) to $52.43 on average volume. Throughout the day, 5,257,755 shares of Eli Lilly and Company exchanged hands as compared to its average daily volume of 4,840,000 shares. The stock ranged in price between $52.33-$53.09 after having opened the day at $52.99 as compared to the previous trading day's close of $53.04. Other companies within the Drugs industry that declined today were: BioScrip ( BIOS), down 18.6%, Mirati Therapeutics ( MRTX), down 12.1%, ImmuCell Corporation ( ICCC), down 10.5% and Amyris ( AMRS), down 10.2%.

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. Eli Lilly and Company has a market cap of $60.8 billion and is part of the health care sector. Shares are up 9.3% year to date as of the close of trading on Monday. Currently there are 4 analysts that rate Eli Lilly and Company a buy, 1 analyst rates it a sell, and 7 rate it a hold.

TheStreet Ratings rates Eli Lilly and Company as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, attractive valuation levels and increase in stock price during the past year. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.

On the positive front, GW Pharmaceuticals PLC ADR ( GWPH), up 68.6%, Genvec ( GNVC), up 35.1%, Acura Pharmaceuticals ( ACUR), up 27.5% and Skystar Bio-Pharmaceutical Company ( SKBI), up 24.9% , were all gainers within the drugs industry with Teva Pharmaceutical Industries ( TEVA) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.
null

If you liked this article you might like

Allergan's Restasis Patent Transfer to Face Precedent-Setting Legal Battle

Eli Lilly Still Looking for Lower Prices

Is Lilly Headed for the Valley?

Walmart, With Extra $10M Fund, Is Among 7 Giving for Hurricane Irma Relief